Related Experiment Video

Updated: Jun 24, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K

Effectiveness of nirsevimab introduction against respiratory syncytial virus in the Valencian Community: A

Pablo Estrella-Porter1, Carolina Blanco-Calvo2, Ana Sofia Lameiras-Azevedo3

  • 1Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain; Preventive Medicine, Hospital Clínico Universitario de Valencia, Av. de Blasco Ibáñez 17, 46010 Valencia, Spain.

Vaccine
|June 4, 2024
PubMed

Insights

Nirsevimab prophylaxis significantly reduced respiratory syncytial virus (RSV) incidence and hospitalizations in young children. The campaign achieved high coverage and demonstrated substantial effectiveness in preventing RSV cases.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Public Health

Background:

  • Respiratory syncytial virus (RSV) poses a significant health burden in children, leading to numerous hospitalizations, particularly in infants under one year old.
  • Nirsevimab, a long-acting monoclonal antibody, was implemented for RSV prevention during the 2023-2024 season in the Valencian Community, Spain.

Purpose of the Study:

  • To evaluate the impact, coverage, and effectiveness of nirsevimab as a universal pre-exposure prophylaxis for infants.
  • To assess the reduction in RSV incidence and hospitalizations among immunized children.

Main Methods:

  • Observational study analyzing data from over 27,000 susceptible children in the Valencian Community.
  • Comparison of RSV incidence and hospitalization rates between immunized (nirsevimab) and non-immunized children.

Main Results:

  • The nirsevimab campaign achieved 88.5% coverage, with over 24,000 children immunized.
  • Immunized children showed a threefold reduction in RSV incidence and nearly twofold lower hospitalization rates for acute respiratory infections.
  • The number needed to immunize (NNI) to prevent one RSV case was 63.

Conclusions:

  • Nirsevimab demonstrated preliminary positive impact as a public health intervention for RSV prevention in young children.
  • High coverage and effectiveness were observed, suggesting a significant reduction in RSV-related morbidity.

Keywords:
ChildrenImmunization campaignNirsevimabPassive immunizationRSVRespiratory syncytial virus infections

More Related Videos

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.6K

Related Concept Videos

Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
420
Respiratory Assessment: Purpose and Indications01:19

Respiratory Assessment: Purpose and Indications

Respiratory assessment is a cornerstone of nursing assessments, crucial for the early detection of patient deterioration. This evaluation transcends routine procedures, representing a critical skill nurses must master to ensure optimal patient care.
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
1.1K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
208
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
196
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
132
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
248